Press Release Archive

 
10.27.2020 - FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
*/ /*-->*/ /*-->*/

-Filings based on robust abrocitinib clinical trial data demonstrating significant symptom improvement versus placebo as well as a consistent safety profile-

 
10.27.2020 - PFIZER REPORTS THIRD-QUARTER 2020 RESULTS
*/
 
10.21.2020 - Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020
*/ /*-->*/ /*-->*/
     
    10.09.2020 - PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
    */ /*-->*/ /*-->*/

    NEU-ISENBURG, Germany & FRANKFURT, Germany & NEW YORK--(BUSINESS WIRE)-- The German Breast Group (GBG) and Pfizer Inc.

     
    10.08.2020 - Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
    */ /*-->*/ /*-->*/

    – Results demonstrated improved treatment burden with once-weekly injection –

     
    10.07.2020 - Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
    */ /*-->*/ /*-->*/

    NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.

     
    10.06.2020 - BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
    • Rolling review accepted by the EMA based on available preclinical and clinical data for BNT162b2 to date
    • BioNTech and Pfizer will continue regular and open dialogue with the EMA providing results from their ongoing Phase 3 study

    NEW YORK and MAINZ, GERMANY, October 6, 2020 — Pfizer Inc.

     
    10.01.2020 - Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy
    */ /*-->*/ /*-->*/

    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from the U.S. Food and Drug Administration (FDA).

     
    09.28.2020 - U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
    */ /*-->*/ /*-->*/

    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.

     
    09.24.2020 - Pfizer Declares Fourth-Quarter 2020 Dividend
    */ /*-->*/ /*-->*/

    Board of Directors approves quarterly cash dividend of $0.38 per share

     
    09.23.2020 - FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma
    */ /*-->*/ /*-->*/

    If approved, XALKORI would be the first biomarker-driven therapy for Pediatric ALK-positive Anaplastic Large Cell Lymphoma

     
    09.22.2020 - Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts
    */ /*-->*/ /*-->*/

    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2020.

     
    09.18.2020 - Pfizer to Present Latest Scientific Advancements from Its Industry- Leading Portfolio at the ESMO Virtual Congress 2020

    Full data from the Phase 3 CROWN study in lung cancer will be presented during the Presidential Symposium

     
    09.18.2020 - BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

    Rockland, MA and New York, US, September 18, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.

     
    09.15.2020 - Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
    */ /*-->*/ /*-->*/
    • Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3
    • 27 key programs highlighted, including assets that could potentially contribute revenu
     
    09.14.2020 - Pfizer Hosts Virtual Investor Day
    */
     
    09.12.2020 - Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
    */ /*-->*/ /*-->*/

    NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and

     
    09.11.2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
    */ /*-->*/ /*-->*/

    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the J.P. Morgan 11th Annual U.S. All Stars Conference on Wednesday, September 16, 2020 at 1:00 p.m. EDT.

     
    09.10.2020 - Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020
    */
     
    09.09.2020 - Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19
    */ /*-->*/ /*-->*/
    • Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge

      Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

       

      Online Pfizer Press Kit